Abstract:Validated liquid chromatography/tandem mass spectrometric (LC/MS/MS) methods are now widely used for quantitation of drugs in post-dose (incurred) biological samples for the assessment of pharmacokinetic parameters, bioavailability and bioequivalence. In accordance with the practice currently accepted within the pharmaceutical industry and the regulatory bodies, validation of a bioanalytical LC/MS/MS method is performed using standards and quality control (QC) samples prepared by spiking the drug (the analyte) into the appropriate blank biological matrix (e.g. human plasma). The method is then declared to be adequately validated for analyzing incurred biological samples. However, unlike QC samples, incurred samples may contain an epimer or another type of isomer of the drug, such as a Z or E isomer. Such a metabolite will obviously interfere with the selected reaction monitoring (SRM) transition used for the quantitation of the drug. The incurred sample may also contain a non-isomeric metabolite having a molecular mass different from that of the drug (such an acylglucuronide metabolite) that can still contribute to (and hence interfere with) the SRM transition used for the quantitation of the drug. The potential for the SRM interference increases with the use of LC/MS/MS bioanalytical methods with very short run times (e.g. 0.5 min). In addition, a metabolite can potentially undergo degradation or conversion to revert back to the drug during the multiple steps of sample preparation that precede the introduction of the processed sample into the LC/MS/MS system. In this paper, we recommend a set of procedures to undertake with incurred samples, as soon as such samples are available, in order to establish the validity of an LC/MS/MS method for analyzing real-life samples. First, it is recommended that the stability of incurred samples be investigated 'as is' and after sample preparation. Second, it is recommended that potential SRM interference be investigated by analyzing the incurred samples using the same LC/MS/MS method but with the additional incorporation of the SRM transitions attributable to putative metabolites (multi-SRM method). The metabolites monitored will depend on the expected metabolic products of the drug, which are predictable based on the functional groups present in the chemical structure of the drug. Third, it is recommended that potential SRM interference be further investigated by analyzing the incurred samples using the multi-SRM LC/MS/MS method following the modification of chromatographic conditions to enhance chromatographic separation of the drug from any putative metabolites. We will demonstrate the application of the proposed strategy by using a carboxylic acid containing drug candidate and its acylglucuronide as a putative metabolite. Plasma samples from the first-in-man (FIM) study of the drug candidate were used as the incurred samples.

Interlaboratory evaluation of LC–MS-based biomarker assays

Intersubject and Intrasubject Variability of Potential Plasma and Urine Metabolite and Protein Biomarkers in Healthy Human Volunteers

Interlaboratory Comparison of Antibody-Free LC-MS/MS Measurements of C-peptide and Insulin

Standardization of PTH measurement by LC-MS/MS: a promising solution for interassay variability

Evolution of LC–MS/MS in clinical laboratories

Signal interference between drugs and metabolites in LC-ESI-MS quantitative analysis and its evaluation strategy

Challenges in the Metabolomics-Based Biomarker Validation Pipeline

Study on the Effect of Calibration Standards Prepared with Different Matrix on the Accuracy of Bile Acid Quantification Using LC-MS/MS.

The Great Importance of Normalization of LC–MS Data for Highly‐accurate Non‐targeted Metabolomics

High Tolerance to Instrument Drifts by Differential Chemical Isotope Labeling LC-MS: A Case Study of the Effect of LC Leak in Long-Term Sample Runs on Quantitative Metabolome Analysis.

Internal standard variability: root cause investigation, parallelism for evaluating trackability and practical considerations

Normalization Approach by a Reference Material to Improve LC-MS-Based Metabolomic Data Comparability of Multibatch Samples.

Single Isotopologue for In-Sample Calibration and Absolute Quantitation by LC-MS/MS

A Strategy for A Post-Method-Validation Use of Incurred Biological Samples for Establishing the Acceptability of A Liquid Chromatography/Tandem Mass-Spectrometric Method for Quantitation of Drugs in Biological Samples

Interlaboratory comparison study of immunosuppressant analysis using a fully automated LC-MS/MS system

Towards Unbiased Evaluation of Ionization Performance in LC-HRMS Metabolomics Method Development

Longitudinal analysis of external quality assessment of immunoassay-based steroid hormone measurement indicates potential for improvement in standardization

Use of Nonhuman Sera as a Highly Cost-Effective Internal Standard for Quantitation of Multiple Human Proteins Using Species-Specific Tryptic Peptides: Applicability in Clinical LC-MS Analyses

Survey of peptide quantification methods and comparison of their reproducibility: A case study using oxytocin

Strategies for using post-column infusion of standards to correct for matrix effect in LC-MS-based quantitative metabolomics

Validation of two LCHRMS methods for large-scale untargeted metabolomics of serum samples: Strategy to establish method fitness-for-purpose